Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up

The authors report the use of topical recombinant human nerve growth factor cenegermin 0.02% in 5 patients diagnosed with neurotrophic keratopathy (NK) in a real-life setting. These 5 patients affected with stage II and III NK mainly of herpetic cause received cenegermin six times daily for 8 weeks....

Descripción completa

Detalles Bibliográficos
Autores principales: García-Delpech, Salvador, Udaondo, Patricia, Fernández-Santodomingo, Alex Samir, García-Teillard, Damian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459538/
https://www.ncbi.nlm.nih.gov/pubmed/36160492
http://dx.doi.org/10.1159/000525923

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9459538/
https://www.ncbi.nlm.nih.gov/pubmed/36160492
http://dx.doi.org/10.1159/000525923

Ejemplares similares